Where this device will fit in with other emerging options remains to be seen, but it might hold an advantage in large annuli.

The novel dissolvable therapy had a 93.2% probability of being cost-effective at a modest willingness-to-pay level.

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Roxana Mehran talks with Robert Harrington, the new Dean of Weill Cornell Medicine, about his move to New York and plans for ...

Ten years after learning their polygenic risk score, patients had fewer events—perhaps due to greater use of statin therapy.

Limus-based devices, rather than being a substitute for paclitaxel as they were once seen, are coming of age in peripheral ...

Nontraditional risk factors, particularly migraine with aura, play a major role in patients under 50 years old.

Not everyone is sold on the benefits of early ezetimibe use, especially given the modest effect seen in IMPROVE-IT.

The 8-year data may hold value for TAVI—the newest Sapien valve uses the same tissue—but many other variables differ.

Leslie Cho and Robert Roswell explain how the rollback of diversity, equity, and inclusion initiatives will impact clinical research, patient care, and healthy equity.